vs
Doximity, Inc.（DOCS）与Indivior Pharmaceuticals, Inc.（INDV）财务数据对比。点击上方公司名可切换其他公司
Indivior Pharmaceuticals, Inc.的季度营收约是Doximity, Inc.的1.9倍（$357.0M vs $185.1M），Doximity, Inc.净利率更高（33.3% vs 28.9%，领先4.4%）
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
Indivior是一家全球专科制药企业，专注于开发和商业化针对阿片类物质使用障碍、酒精依赖及相关精神健康疾病的循证治疗方案，核心市场覆盖北美与欧洲，旗下多款获批疗法服务于医疗需求未被充分满足的患者群体。
DOCS vs INDV — 直观对比
营收规模更大
INDV
是对方的1.9倍
$185.1M
净利率更高
DOCS
高出4.4%
28.9%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.1M | $357.0M |
| 净利润 | $61.6M | $103.0M |
| 毛利率 | 89.9% | 82.1% |
| 营业利润率 | 38.9% | 22.7% |
| 净利率 | 33.3% | 28.9% |
| 营收同比 | 9.8% | — |
| 净利润同比 | -18.1% | 390.5% |
| 每股收益（稀释后） | $0.31 | $0.79 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCSINDV
| Q4 25 | $185.1M | $357.0M | ||
| Q3 25 | $168.5M | $314.0M | ||
| Q2 25 | $145.9M | $302.0M | ||
| Q1 25 | $138.3M | $266.0M | ||
| Q4 24 | $168.6M | — | ||
| Q3 24 | $136.8M | $307.0M | ||
| Q2 24 | $126.7M | $299.0M | ||
| Q1 24 | $118.1M | — |
净利润DOCSINDV
| Q4 25 | $61.6M | $103.0M | ||
| Q3 25 | $62.1M | $42.0M | ||
| Q2 25 | $53.3M | $18.0M | ||
| Q1 25 | $62.5M | $47.0M | ||
| Q4 24 | $75.2M | — | ||
| Q3 24 | $44.2M | $22.0M | ||
| Q2 24 | $41.4M | $-97.0M | ||
| Q1 24 | $40.6M | — |
毛利率DOCSINDV
| Q4 25 | 89.9% | 82.1% | ||
| Q3 25 | 90.3% | 73.2% | ||
| Q2 25 | 89.2% | 82.8% | ||
| Q1 25 | 89.5% | 83.1% | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 90.0% | 78.5% | ||
| Q2 24 | 89.3% | 73.6% | ||
| Q1 24 | 89.4% | — |
营业利润率DOCSINDV
| Q4 25 | 38.9% | 22.7% | ||
| Q3 25 | 37.8% | 13.7% | ||
| Q2 25 | 37.4% | 23.8% | ||
| Q1 25 | 35.2% | 24.8% | ||
| Q4 24 | 47.4% | — | ||
| Q3 24 | 38.8% | 11.4% | ||
| Q2 24 | 36.4% | -39.5% | ||
| Q1 24 | 35.5% | — |
净利率DOCSINDV
| Q4 25 | 33.3% | 28.9% | ||
| Q3 25 | 36.8% | 13.4% | ||
| Q2 25 | 36.5% | 6.0% | ||
| Q1 25 | 45.2% | 17.7% | ||
| Q4 24 | 44.6% | — | ||
| Q3 24 | 32.3% | 7.2% | ||
| Q2 24 | 32.7% | -32.4% | ||
| Q1 24 | 34.4% | — |
每股收益（稀释后）DOCSINDV
| Q4 25 | $0.31 | $0.79 | ||
| Q3 25 | $0.31 | $0.33 | ||
| Q2 25 | $0.27 | $0.14 | ||
| Q1 25 | $0.31 | $0.38 | ||
| Q4 24 | $0.37 | — | ||
| Q3 24 | $0.22 | $0.16 | ||
| Q2 24 | $0.21 | $-0.72 | ||
| Q1 24 | $0.20 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $64.8M | $195.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $979.3M | $-98.0M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOCSINDV
| Q4 25 | $64.8M | $195.0M | ||
| Q3 25 | $169.2M | $445.0M | ||
| Q2 25 | $137.3M | $510.0M | ||
| Q1 25 | $209.6M | $373.0M | ||
| Q4 24 | $165.3M | — | ||
| Q3 24 | $184.2M | — | ||
| Q2 24 | $111.4M | — | ||
| Q1 24 | $96.8M | — |
股东权益DOCSINDV
| Q4 25 | $979.3M | $-98.0M | ||
| Q3 25 | $1.1B | $-207.0M | ||
| Q2 25 | $1.0B | $-257.0M | ||
| Q1 25 | $1.1B | $-285.0M | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $961.2M | $-310.0M | ||
| Q2 24 | $913.6M | $-281.0M | ||
| Q1 24 | $901.4M | — |
总资产DOCSINDV
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.2B | $1.5B | ||
| Q1 25 | $1.3B | $1.4B | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $1.1B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.9M | $-221.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-245.0M |
| 自由现金流率自由现金流/营收 | — | -68.6% |
| 资本支出强度资本支出/营收 | — | 6.7% |
| 现金转化率经营现金流/净利润 | 0.99× | -2.15× |
| 过去12个月自由现金流最近4个季度 | — | $-93.0M |
8季度趋势，按日历期对齐
经营现金流DOCSINDV
| Q4 25 | $60.9M | $-221.0M | ||
| Q3 25 | $93.9M | $-39.0M | ||
| Q2 25 | $62.1M | $158.0M | ||
| Q1 25 | $98.5M | $75.0M | ||
| Q4 24 | $65.2M | — | ||
| Q3 24 | $68.3M | $2.0M | ||
| Q2 24 | $41.2M | $88.0M | ||
| Q1 24 | $63.9M | — |
自由现金流DOCSINDV
| Q4 25 | — | $-245.0M | ||
| Q3 25 | — | $-59.0M | ||
| Q2 25 | — | $141.0M | ||
| Q1 25 | — | $70.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-5.0M | ||
| Q2 24 | — | $84.0M | ||
| Q1 24 | — | — |
自由现金流率DOCSINDV
| Q4 25 | — | -68.6% | ||
| Q3 25 | — | -18.8% | ||
| Q2 25 | — | 46.7% | ||
| Q1 25 | — | 26.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1.6% | ||
| Q2 24 | — | 28.1% | ||
| Q1 24 | — | — |
资本支出强度DOCSINDV
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 6.4% | ||
| Q2 25 | — | 5.6% | ||
| Q1 25 | 0.0% | 1.9% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 2.3% | ||
| Q2 24 | 0.0% | 1.3% | ||
| Q1 24 | 0.0% | — |
现金转化率DOCSINDV
| Q4 25 | 0.99× | -2.15× | ||
| Q3 25 | 1.51× | -0.93× | ||
| Q2 25 | 1.16× | 8.78× | ||
| Q1 25 | 1.58× | 1.60× | ||
| Q4 24 | 0.87× | — | ||
| Q3 24 | 1.55× | 0.09× | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 1.57× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
INDV
| Sublocade | $233.0M | 65% |
| Sublingual And Other | $69.0M | 19% |
| Other | $49.0M | 14% |
| Perseris | $6.0M | 2% |
